Search
-
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering
April 26, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VFO.F) (“Hemostemix” or the “Company”)…
-
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
April 9, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
April 8, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) (“Hemostemix” or the “Company”) is…
-
Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities
March 18, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to…
-
Fully funded with strong IP Portfolio, Hemostemix marches forward towards FDA Phase II Clinical Trial Completion
Hemostemix Inc. (TSXV: HEM | OTC: HMTXF) continues to move forward with its FDA Phase II clinical trial…
-
Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
February 11, 2021 (Source) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to…
-
Hemostemix Announces HS 12 – 01 Clinical Trial Completion of Subjects’ Follow-Up Visits at the End of March and Warrants Extended and Repriced
January 28, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to…
-
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
January 22, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) (“Hemostemix” or the “Company”) is pleased to announce…
-
Hemostemix CEO on ACP’s Response to Ischemia in the Circulatory System
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…